Eli Lilly and Company (NYSE:LLY - Get Free Report) traded up 1% during mid-day trading on Wednesday . The company traded as high as $846.01 and last traded at $836.00. 941,914 shares changed hands during trading, a decline of 72% from the average session volume of 3,420,434 shares. The stock had previously closed at $827.54.
Analysts Set New Price Targets
LLY has been the subject of several research reports. Guggenheim cut their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday, April 14th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Finally, StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,017.00.
View Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market capitalization of $781.40 billion, a price-to-earnings ratio of 70.38, a PEG ratio of 1.40 and a beta of 0.51. The business's fifty day simple moving average is $827.10 and its 200 day simple moving average is $818.99.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.
Insiders Place Their Bets
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.13% of the company's stock.
Institutional Trading of Eli Lilly and Company
A number of hedge funds have recently bought and sold shares of the business. CWA Asset Management Group LLC grew its stake in shares of Eli Lilly and Company by 11.9% during the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after acquiring an additional 724 shares during the period. Centerpoint Advisory Group bought a new position in Eli Lilly and Company during the fourth quarter worth about $514,000. Kentucky Trust Co purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $834,000. Proficio Capital Partners LLC raised its position in shares of Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after purchasing an additional 1,562 shares during the period. Finally, Cooper Financial Group lifted its stake in shares of Eli Lilly and Company by 35.5% during the 4th quarter. Cooper Financial Group now owns 2,655 shares of the company's stock valued at $2,050,000 after buying an additional 695 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
